Working… Menu
Trial record 49 of 106 for:    IVERMECTIN

Treatment of Pediculosis (Head Lice) in Senegal (IVERAZITH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03578679
Recruitment Status : Completed
First Posted : July 6, 2018
Last Update Posted : February 27, 2019
Information provided by (Responsible Party):
Institut de Recherche pour le Developpement

Brief Summary:

This is a prospective single-arm interventional study evaluating Therapeutic efficacy of a combination of two pharmaceutical drugs, Azithromycin (AZIT) and Ivermectin (IVER) administered orally in the treatment of head lice infestations. In case of persistence of lice and / or nits on day 7, a second oral administration of combination Azithromycin + Ivermectin will be considered.

The duration of the study period is 4 months, ie 1 month and ½ of inclusion and 2 months and ½ feedback. There will be a site initiation visit "site initiation visit" before inclusions at D-7, two monitoring visits and a closing visit "close out visit" at the end of the follow-up at 4 months.

Condition or disease Intervention/treatment Phase
Pediculoses Drug: Ivermectin Oral Product Not Applicable

Detailed Description:

The investigators will perform a clinical trial of efficacy, single-arm, until D28 from volunteer subjects infested with head lice.

The two villages of the study (Dielmo and Ndiop) will be visited to explain the protocol and obtain community permission to work on it. Schools will also be visited to inform teachers and explain the protocol. The search for lice will be done by village women recruited for this purpose. A systematic census by family will be performed. A clinical examination of the hair will detect the persons infested with lice. On D-1, individual informed consent (an assent for participants between the ages of 15 and 18) will be systematically obtained before inclusion.

At D1, an interview and a complete clinical examination will be done on each subject consenting. All volunteers meeting the inclusion criteria will be taken on a single arms. For each voluntary participant selected fasting 1 hour before, the treatments will be administered by the investigators of the study. After taking the AZIT + IVER dose, each treated volunteer will be followed for 1 hour to observe the appearance of any side effects, then a breakfast will be offered. Head lice and nits will be searched on D1, D7, D15 and D28 for each volunteer and the hair taken on D2, D5, D7, D15 and D28. Possibly, before each treatment, Stool samples will be taken systematically on day 1 and after treatment on day 15 at any participant infested with head lice to identify intestinal parasites (load parasite in helminthiasis) to evaluate also the efficacy of ivermectin on these parasites. Sociodemographic, clinical, dose and type of material taken biological will be documented. Data on co-infections (body lice, Sarcoptes scabeii) will also be collected and reported on the study register. Each volunteer will have an identification number (ID). Only, the principal investigator, the coordinator and the investigators can access sensitive information if they exist. Data will be entered immediately by a data entry agent. The investigators will sleep on the sites and will face possible cases of effects undesirable. Regular visits will be scheduled on D2, D5, D7, D15 and D28. A clinical monitor will stay with the team on the field of D2, D5, D7, D15 and D28. A Clinical Research Organisation (CRO) will ensure the external monitoring of the study (1 site initiation visit, 2 monitoring visits and 1 visit closing of the test). It will also be scheduled for a visit by Comité National d'Ethique en Santé (CNERS) members on the field according to their schedule. All willing participants and completing the eligibility criteria for entry into this study, will be taken on a single treatment arm Azithromycin-Ivermectin in orodispersible tablets. The evaluation of the answer therapy will be done on D7 and / or D15.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 450 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Interventional prospective study with only one arm
Masking: None (Open Label)
Masking Description: Evaluation of therapeutic efficacy of a combination of two usual drugs.
Primary Purpose: Treatment
Official Title: Study of the Therapeutic Efficacy of the Combination Azithromycin + Ivermectin in the Treatment of Pediculosis in Senegal (IVERAZITH)
Actual Study Start Date : July 11, 2018
Actual Primary Completion Date : January 31, 2019
Actual Study Completion Date : February 24, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Ivermectin

Arm Intervention/treatment
Experimental: HEGOR/AZICUR shampoo solution
At D1, shampoo AZICUR liquid formulation in infested persons aged 0 to 6 years and / or less than 15 kg, also apply the combination HEGOR / AZICUR solution shampoo in women pregnant or lactating women not eligible for treatment with Ivermectin, to prevent them from contaminate treated participants who are very close to them or share the same bed or same bench table at school.
Drug: Ivermectin Oral Product
treatment of pediculosis (head lice)
Other Name: Azithromycine oral Product

Primary Outcome Measures :
  1. Parasiticidal efficacy: disappearance of head lice (zero lice) on day 7 [ Time Frame: Day 7 ]

    Evaluating the efficacy of the treatment of combination of two usual drugs from volunteer subjects infested with head lice.

    To study the therapeutic efficacy of the combination Azithromycin-Ivermectin administered orally in the treatment of head lice infestations (in case of persistence of lice at D7 a second oral administration of the combination azithromycin-Ivermectin will be considered).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Children, adolescents and adults infested with head lice and / or co-infestation head lice and body lice
Accepts Healthy Volunteers:   No

Includes lists of Inclusion Criteria:

  • body weight ≥ 15 kg for oral administration to ivermectin, • Obtain the signed informed consent of the parent or caregiver for his participation in the study.

Includes lists of Criteria Exclusion:

  • Refusal of participation,

    • Non-residents in the villages during the study period,
    • body weight <15 kg not eligible for oral administration with ivermectin,
    • Pregnant women, who in the context of the daily medical and epidemiological monitoring of the population of Dielmo-like that of Ndiop- are identified and very early at the looking at the first signs of conception in a pregnant woman from her state of pregnancy on the basis of a proven test. In addition, before any treatment with ivermectin, will be systematically requested from each of the target women of reproductive age if she is pregnant
    • Women breastfeeding at the time of the study,

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03578679

Layout table for location information
Institut de Recherche pour le Developpement
Dakar, Senegal, 18524
Sponsors and Collaborators
Institut de Recherche pour le Developpement
Layout table for investigator information
Study Director: Cheikh Sokhna, PhD Institut de Recherche pour le Developpement

Layout table for additonal information
Responsible Party: Institut de Recherche pour le Developpement Identifier: NCT03578679     History of Changes
Other Study ID Numbers: SEN17/16
First Posted: July 6, 2018    Key Record Dates
Last Update Posted: February 27, 2019
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: oral communications and publications

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lice Infestations
Ectoparasitic Infestations
Skin Diseases, Parasitic
Parasitic Diseases
Skin Diseases, Infectious
Skin Diseases
Antiparasitic Agents
Anti-Infective Agents